Latest Regulatory Delays News

Reef Casino Trust has issued a second supplementary target’s statement as the takeover bid by Iris Cairns Property Pty Ltd extends to August 2026 due to delayed casino licensing approvals. The board maintains its recommendation for unitholders to accept the offer, pending regulatory outcomes and expert advice.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Orezone Gold Corporation reported a robust 33% increase in revenue for FY2025, underpinned by higher gold prices and the start of hard rock production at Bomboré. The company also announced a strategic acquisition of the Casa Berardi gold mine in Canada.

Platformo Ltd reported a modest 5% revenue increase in 2025 driven by its Malaysian subsidiary Biztrak, but faced a higher net loss due to regulatory delays and increased corporate advisory costs.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Caravel Minerals confirms its Definitive Feasibility Study for the Caravel Copper Project remains on track for mid-2026, while regulatory water investigations push the Final Investment Decision to late 2027. Meanwhile, strategic talks with Adani advance steadily.

Riversgold Limited has resolved all objections to its Mining Lease application for the Northern Zone Gold Project near Kalgoorlie, paving the way for imminent lease approval and advancing its partnership with MEGA Resources.

ADX Energy has restarted flow testing at its Welchau-1 well in Austria after regulatory delays, aiming to confirm the commercial viability of light oil and gas-condensate reservoirs in the Reifling Formation.

Iris Cairns Property Trust has confirmed new funding arrangements and plans to extend its takeover offer period for Reef Casino Trust, navigating regulatory hurdles and reassuring investors of its financial backing.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Carbine Resources has secured key access agreements and is progressing regulatory approvals for its silica sand projects, maintaining a strong cash position as field activities prepare to restart in early 2026.